The Journal of Clinical Psychiatry

Author Index to Volume 69: January 2008 Through December 2008

Aaronson CJ, Shear MK, Goetz RR, Allen LB, Barlow DH, White KS, Ray S, Money R, Saksa JR, Woods SW, Gorman JM. Predictors and time course of response among panic disorder patients treated with cognitive-behavioral therapy. Mar 418–424

Aaronson ST see Tohen M

Abel KM, Heatlie HF, Howard LM, Webb RT. Sex- and age-specific incidence of fractures in mental illness: a historical, population-based cohort study. Sept 1398–1403

Ackerman SH see Goldberg JF

Adams AS see Law MR

Adler LA. Diagnosing and treating adult ADHD and comorbid conditions. Nov e31

Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, Biederman J, on behalf of the 303 Study Group. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. Sept 1364–1373

Adler LA see Robison RJ; Spencer TJ

Adli M see Berghöfer A

Aharonovich E see Hasin DS

Ahmed S see Rothbaum BO

Ahn YM see Chang JS

Al Jurdi RK see Marangell LB

Albert U see Maina G

Alda M see Berghöfer A; McGirr A

Alderson D see Hasin DS

Alho H see Muhonen LH

Alisic E, van der Schoot TAW, van Ginkel JR, Kleber RJ. Looking beyond posttraumatic stress disorder in children: posttraumatic stress reactions, posttraumatic growth, and quality of life in a general population sample. Sept 1455–1461

Allen A see Dell'Osso B

Allen JC Jr see Marangell LB

Allen LB see Aaronson CJ

Allen MH see Marangell LB

Allen RR see Morrato EH

Almeida OP see Ford AH

Alpert JE see Gilmer WS

Altoè G see Moscardino U

Alvarez E see Pascual JC

Ammerman DK see Coley KC

Amminger GP see Berger GE

Amsterdam JD see Tohen M

Anders M see Dossenbach M

Andersen S see Lauriello J

Anderson CS see Spencer TJ

Anderson VA see Karsz FR

Andersson G see Cuijpers P

Andreotti CF see Petersen TJ

Anestin AS see Richardson J; Steiger H

Angarita GA see Loebl T

Anglin DM, Malaspina D. Ethnicity effects on clinical diagnoses compared to best-estimate research diagnoses in patients with psychosis: a retrospective medical chart review. June 941–945

Anglin DM, Malaspina D. Racial and ethnic effects on psychotic psychiatric diagnostic changes from admission to discharge: a retrospective chart review. Mar 464–469

Angst J see Hegerl U

Anonychuk AM see Steiner M

Antony JT, Elias A, Chacko F, Rajan B. Is clozapine safe in patients with preexisting epilepsy? a report of 2 cases [letter]. Feb 328–329

Arango C see Fraguas D

Araújo Leite MA see Fontenelle LF

Arendt M see Sher L

Armani A see Mauri M

Armitage TL see Hudson TJ

Arnold LE see Findling RL

Arnold LM. Management of fibromyalgia and comorbid psychiatric disorders. Suppl 2, 14–19

Arnold LM, Bradley LA, Clauw DJ, Glass JM, Goldenberg DL. Evaluating and diagnosing fibromyalgia and comorbid psychiatric disorders. Oct e28

Arnold LM, Jain R, Glazer WM. Pain and the brain. Sept e25

Arvekvist R see Weisler RH

Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. Oct 1580–1588

Avery DH, Isenberg KE, Sampson SM, Janicak PG, Lisanby SH, Maixner DF, Loo C, Thase ME, Demitrack MA, George MS. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. Mar 441–451

Avila M see Nejtek VA

Axelson DA see Goldstein BI

Axia G see Moscardino U

Aylward EH see Beglinger LJ

Azoulay L, Blais L, Koren G, LeLorier J, Bérard A. Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover study. Apr 526–532

Baca-Garcia E see Perez-Rodriguez MM

Bae S see Nejtek VA

Baer L, Minichiello WE. Reasons for inadequate utilization of cognitive-behavioral therapy for obsessive-compulsive disorder [letter]. Apr 676

Baethge C see Berghöfer A

Baghai TC, Varallo-Bedarida G, Born C, Häfner S, Schule C, Eser D, von Schacky C, Rupprecht R, Bondy B. Polymorphism in the angiotensin-converting enzyme gene is associated with smoking behavior [letter]. Dec 1983–1985

Bai F see Yu H

Bailine SH see Husain MM; McClintock SM

Bain EE see Bonne O

Baker B see Dell'Osso B

Baker CB see Woods SW

Baker DG see Friedman MJ

Balanza-Martinez V see Martinez-Aran A

Baldwin DS see Rothbaum BO

Ballard CG see Wilcock GK

Banov M see Tohen M

Banti S see Borri C

Barbeito S see González-Pinto A

Barbui C see Cipriani A; Watanabe N

Bardenstein L see Tohen M

Barlow DH see Aaronson CJ

Barnow S see Spitzer C

Barr RS see Culhane MA

Barsoum P see Mamo DC

Bartko JJ see Steinberg EM

Batra S see Reeves H

Bauer M see Berghöfer A

Bauer MS see Marangell LB

Becker MA. Review of Gitlow S: *Substance Use Disorders: A Practical Guide, 2nd ed.* July 1194

Becker T see Weinmann S

Beckman V see Rankin KP

Begley A see Karp JF

Beglinger LJ, Paulsen JS, Watson DB, Wang C, Duff K, Langbehn DR, Moser DJ, Paulson HL, Aylward EH, Carlozzi NE, Queller S, Stout JC, the PREDICT-HD Investigators of the Huntington Study Group. Obsessive and compulsive symptoms in prediagnosed Huntington's disease. Nov 1758–1765

Belden AC see Luby JL

Belik S-L see Bolton JM

Benabarre A see Martinez-Aran A

Benazzi F. Continuum hypothesis of mood disorders [letter with reply]. July 1187–1188

Benazzi F. Misdiagnosis of bipolar II disorder as major depressive disorder [letter with reply]. Mar 501–503

Benazzi F see Dilsaver SC

Bérard A see Azoulay L

Berger GE, Proffitt T-M, McConchie M, Kerr M, Markulev C, Yuen HP, O'Donnell C, Lubman D, Polari A, Wood S, Amminger GP, McGorry PD. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-

blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. Nov 1702–1714
Bergeson S see Gelenberg AJ
Berghöfer A, Alda M, Adli M, Baethge C, Bauer M, Bschor T, Glenn T, Grof P, Müller-Oerlinghausen B, Rybakowski J, Suwalska A, Pfennig A. Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. Dec 1860–1868
Berman RM. Reply to Rakofsky JJ: Is aripiprazole an efficacious adjunct for unipolar depression? [letter] June 1021–1022
Berman RM see Newcomer JW; Trivedi MH
Bernadt M see Patel MX
Berner JE. Case of sodium oxybate treatment of tardive dyskinesia and bipolar disorder [letter]. May 862
Bernhard B see Dittmann S
Bernstein CA see Brogan K
Bernstein I see Gonzalez R
Bettini A see Borri C
Beyer JL. Evidence-based medicine strategy for achieving remission in bipolar disorder. Suppl 3, 31–37
Bharadwaj R, Grover S. Parkinsonism and akathisia with quetiapine: three case reports [letter]. July 1189–1191
Bhat A see Khan A
Bianchi F see Leo R
Biederman J, Petty CR, Fried R, Kaiser R, Dolan CR, Schoenfeld S, Doyle AE, Seidman LJ, Faraone SV. Educational and occupational underattainment in adults with attention-deficit/hyperactivity disorder: a controlled study. Aug 1217–1222
Biederman J, Seidman LJ, Petty CR, Fried R, Doyle AE, Cohen DR, Kenealy DC, Faraone SV. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder. July 1150–1156
Biederman J see Adler LA
Bielski RJ, Cunningham L, Horrigan JP, Londborg PD, Smith WT, Weiss K. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study. Apr 571–577
Biggs MM see Husain MM; McClintock SM
Bilali S see Gao K
Binder CE see Ravindran AV
Birkenhäger TK see Heijnen WTC
Birmaher B see Brodsky BS; Goldstein BI
Birnbaum RJ see Petersen TJ
Bishop JR see Miller LJ
Bisol LW, Brunstein MG, Ottoni GL, Ramos FLP, Borba DL, Daltio CS, de Oliveira RV, Paz GEG, de Souza SE, Bressan RA, Lara DR. Is flunarizine a long-acting oral atypical antipsychotic? a randomized clinical trial versus haloperidol for the treatment of schizophrenia. Oct 1572–1579
Blais L see Azoulay L
Blais MA see Petersen TJ
Blanco C, Olfson M, Goodwin RD, Ogburn E, Liebowitz MR, Nunes EV, Hasin DS. Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Aug 1276–1280
Blanco C see Daughters SB; Vesga-López O
Bleich S see Mueller A
Blier P see Trivedi MH
Blonde L, Kan HJ, Gutterman EM, L'Italien GJ, Kim MS, Hanssens L, McQuade RD. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. May 741–748
Blow FC see Sajatovic M
Blyta A see Gordon JS,
Bobo WV. Review of Fujii D, Ahmed I (eds): *Spectrum of Psychotic Disorders: Neurobiology, Etiology, and Pathogenesis*. Dec 1987–1988
Bobo WV see Meltzer HY
Bodea-Barothi SP. Review of Cook CCH: *Alcohol, Addiction and Christian Ethics*. Aug 1342
Bogetto F see Maina G
Boggio PS see Fregni F
Bolton JM, Belik S-L, Enns MW, Cox BJ, Sareen J. Exploring the correlates of suicide attempts among individuals with major depressive disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. July 1139–1149
Bond DJ, Noronha MM, Kauer-Sant'Anna M, Lam RW, Yatham LN. Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. Oct 1589–1601
Bondy B see Baghai TC
Bonne O, Vythilingam M, Inagaki M, Wood S, Neumeister A, Nugent AC, Snow J, Luckenbaugh DA, Bain EE, Drevets WC, Charney DS. Reduced posterior hippocampal volume in posttraumatic stress disorder. July 1087–1091
Borba DL see Bisol LW
Born C see Baghai TC; Dittmann S; Hegerl U
Borri C, Mauri M, Oppo A, Banti S, Rambelli C, Ramacciotti D, Montagnani MS, Camilleri V, Cortopassi S, Bettini A, Ricciardulli S, Rucci P, Montaresi S, Cassano GB. Axis I psychopathology and functional impairment at the third month of pregnancy: results from the Perinatal Depression-Research and Screening Unit (PND-ReScU) study. Oct 1617–1624
Bottner A-C see Hegerl U
Bowden C see Tohen M
Bradley LA. Pathophysiologic mechanisms of fibromyalgia and its related disorders. Suppl 2, 6–13
Bradley LA see Arnold LM
Brady KT see Gao K; Rothbaum BO
Bramness JG, Skurtveit S, Neutel CI, Mørland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants: a study of population registry data in Norway. July 1099–1103
Brandon AR, Trivedi MH, Hynan LS, Miltenberger PD, Labat DB, Rifkin JB, Stringer CA. Prenatal depression in women hospitalized for obstetric risk. Apr 635–643
Brann PG see Karsz FR
Braun AR see Daughters SB
Breder C see Newcomer JW
Brent D see Brodsky BS
Brent DA see Sher L
Bressan RA see Bisol LW
Bret ME see Weiner MF
Brewer WJ see Karsz FR
Brodsky BS, Mann JJ, Stanley B, Tin A, Oquendo M, Birmaher B, Greenhill L, Kolko D, Zelazny J, Burke AK, Melhem NM, Brent D. Familial transmission of suicidal behavior: factors mediating the relationship between childhood abuse and offspring suicide attempts. Apr 584–596
Brodsky BS see Mann JJ
Broekaert E see Colins O
Brogan K, Bernstein CA. Review of Barnovitz MA, Joglekar P: *Medical Psychiatry: The Quick Reference*. Oct 1665
Brooks BA. Review of Terr L: *Magical Moments of Change: How Psychotherapy Turns Kids Around*. Nov 1836
Brown ES, Garza M, Carmody TJ. Randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. May 701–705
Brown FW. Review of Spar JE, La Rue A: *Clinical Manual of Geriatric Psychiatry*. Jan 167–168
Brown MZ see Linehan MM
Bruce KR see Richardson J; Steiger H
Brunnauer A, Laux G, David I, Fric M, Hermisson I, Möller H-J. Impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients. Dec 1880–1886
Brunstein MG see Bisol LW
Bryant RA, Creamer M, O'Donnell M, Silove D, McFarlane AC. Multisite study of initial respiration rate and heart rate as predictors of posttraumatic stress disorder. Nov 1694–1701
Bryant RA, Creamer M, O'Donnell ML, Silove D, McFarlane AC. Multisite study of the capacity of acute stress disorder diagnosis to predict posttraumatic stress disorder. June 923–929
Bschor T see Berghöfer A
Buckley PF. Factors that influence treatment success in schizophrenia. Suppl 3, 4–10
Buckley PF. Treating movement disorders and akathisia as side effects of antipsychotic pharmacotherapy. May e14
Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. Suppl 1, 4–17
Bukstein OG see Findling RL
Bulik CM see Javaras KN
Burke AK see Brodsky BS
Burock M see Bystritsky A

Busnello JV see Machado-Vieira R
Busschbach JJV see Soeteman DI
Bystritsky A, Kaplan JT, Feusner JD, Kerwin LE, Wadekar M, Burock M, Wu AD, Iacoboni M. Preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder. July 1092–1098
Bystritsky A, Kerwin L, Feusner J. Pilot study of cranial electrotherapy stimulation for generalized anxiety disorder. Mar 412–417
Bytyqi M see Gordon JS
Calabrese JR. Overview of patient care issues and treatment in bipolar spectrum and bipolar II disorder. June e18
Calabrese JR see Gao K; Nowakowska C; Weisler RH; Youngstrom EA
Calderone A see Mauri M
Calhoun PS, Elter JR, Jones Jr ER, Kudler H, Straits-Tröster K. Hazardous alcohol use and receipt of risk-reduction counseling among U.S. veterans of the wars in Iraq and Afghanistan. Nov 1686–1693
Callahan AM see Goldberg JF
Camacho F see Ravindran AV
Camilleri V see Borri C
Campos JA see Newcomer JW
Capello F see Moscardino U
Carballo JJ see Sher L
Carlat D. Apparent commercial bias in supplement [letter with reply]. June 1020–1021
Carlozzi NE see Beglinger LJ
Carlson BX see Trivedi MH
Carmody TJ see Brown ES
Caroff SN see Satterthwaite TD
Carson WH see Newcomer JW
Carter D see Steiner M
Cartwright J see Fazel S
Caruso KA. Review of Barbaree HE, Marshall WL (eds): *The Juvenile Sex Offender, 2nd ed.* Sept 1504
Case BG see Pundiak TM
Cassano GB see Borri C; Mauri M
Cassidy KA see Sajatovic M
Cather C see Culhane MA
Celic I see van Winkel R
Certa K see Mago R
Cetkovich-Bakmas M see Fleischhacker WW
Ceverino A see Perez-Rodriguez MM
Chacko F see Antony JT
Chang H-C see Su K-P
Chang H-L see Gau SS-F
Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, Kim YS. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. May 720–731
Chang KD. Bipolar spectrum in children and adolescents: developmental issues. Mar e09
Chang KD. Use of atypical antipsychotics in pediatric bipolar disorder. Suppl 4, 4–8
Chang T-J see Lin Y-C
Chaplin WF see Dell'Osso B
Charney DS see Bonne O
Chelminski I see Zimmerman M
Chen H-Z see Lin Y-C
Chen L-A see Nejtek VA
Chen M-C see Lin C-H
Chen S-J see Gau SS-F
Chen Y see Meltzer HY
Chen Y-C see Yeh Y-W
Cheng H see Gau SS-F
Chism LM see Mago R
Chiu T-H see Su K-P
Choi EJ see Lee SJ
Choi SS see Kim J-H
Chou M-C see Gau SS-F
Chou SP see Goldstein RB; Grant BF; Pulay AJ; Stinson FS
Chou W-J see Gau SS-F
Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting. Dec 1938–1947
Churchill R see Cipriani A; Watanabe N
Cifuentes A see Fraguas D
Cipriani A, Furukawa TA, Geddes JR, Malvini L, Signoretti A, McGuire H, Churchill R, Nakagawa A, Barbui C, on behalf of the MANGA Study Group. Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? a systematic review and meta-analysis. Nov 1732–1742
Cipriani A see Watanabe N
Ciranni M, Lindenmayer J-P, Gold J. Efficacy of molindone in treatment-refractory agitated schizophrenia: three case reports [letter]. June 1018–1019
Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM. Early treatment response in alcohol dependence with extended-release naltrexone. Feb 190–195
Claassen C see Husain MM; McClintock SM
Clauw DJ. Assessing and diagnosing fibromyalgia in the clinical setting. Nov e33
Clauw DJ. Pharmacotherapy for patients with fibromyalgia. Suppl 2, 25–29
Clauw DJ see Arnold LM
Coconcea N see Sajatovic M
Coffey BJ see Lyon GJ
Cohen DR see Biederman J
Cohen LS see Yonkers KA
Cohen SJ see Woods SW
Cohen-Mansfield J see Salzman C
Cohn M see Scharf M
Coley KC, Fabian TJ, Kim E, Ammerman DK, Scipio TM, Saul MI, Kim MS, Whitehead R, Ganguli R. Predictors of aripiprazole treatment continuation in hospitalized patients. Sept 1393–1397
Colins O, Vermeiren R, Schuyten G, Broekaert E, Soyez V. Informant agreement in the assessment of disruptive behavior disorders in detained minors in Belgium: a diagnosis-level and symptom-level examination. Jan 141–148
Colom F see Martinez-Aran A
Comparison of Atypicals in First Episode Study Group see Perkins DO
Conlon CJ see Chronis-Tuscano A
Connor KM see Rothbaum BO; Simon NM
Cooper JA see Wilcock GK
Correll CU. Antipsychotic polypharmacy, part 1: shotgun approach or targeted cotreatment? [ASCP Corner]. Apr 674–675
Correll CU. Antipsychotic polypharmacy, part 2: why use 2 antipsychotics when 1 is not good enough? [ASCP Corner] May 860–861
Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. Suppl 4, 26–36
Correll CU. Effect of hyperprolactinemia during development in children and adolescents. Aug e24
Correll CU. Elevated cardiovascular risk in patients with bipolar disorder: when does it start and where does it lead? [commentary] Dec 1948–1952
Correll CU, Kane JM, Manu P. Identification of high-risk coronary heart disease patients receiving atypical antipsychotics: single low-density lipoprotein cholesterol threshold or complex national standard? Apr 578–583
Correll CU see Buckley PF
Corruble E see Perahia DGS
Cortopassi S see Borri C
Cox BJ see Bolton JM
Creamer M see Bryant RA
Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. July 1157–1165
Crow SJ see Javaras KN
Cruz N see Vieta E
Cuijpers P, van Straten A, van Oppen P, Andersson G. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? a meta-analysis of comparative studies. Nov 1675–1685
Culhane MA, Schoenfeld DA, Barr RS, Cather C, Deckersbach T, Freudenreich O, Goff DC, Rigotti NA, Evins AE. Predictors of early abstinence in smokers with schizophrenia. Nov 1743–1750
Culhane MA see Loebl T
Cummings J see Salzman C
Cunha A see Machado-Vieira R
Cunningham L see Bielski RJ
Currier D see Mann JJ
Daban C see Martinez-Aran A
D'Agostino RB see Strom BL
Dahl DC see Reeves H
Daltio CS see Bisol LW
Dandurand C see Richardson J
Daniels JP, Felde A. Quetiapine treatment for mania secondary to brain injury in 2 patients [letter]. Mar 497–498
Dargel S see Dittmann S
Dasgupta K see Rahme E
Daughters SB, Braun AR, Sargeant MN, Reynolds EK, Hopko DR, Blanco C, Lejuez CW. Effectiveness of a brief behavioral treatment for inner-city illicit drug users with

elevated depressive symptoms: the Life Enhancement Treatment for Substance Use (LETS Act!). Jan 122–129
David AS see Patel MX
David I see Brunnauer A
Davidson JRT see Rothbaum BO; Simon NM
Davis JM see Glick ID
Dawson DA see Goldstein RB; Grant BF; Pulay AJ; Stinson FS
Deckersbach T see Culhane MA
de Guzman R see Richardson J
De Hert M see Fleischhacker WW; van Winkel R
DelBello MP. Attention-deficit/hyperactivity disorder: advances in diagnostic and therapeutic approaches. Jan 130
DelBello MP. Mood disorders: assessment, risk factors, and outcome. May 830
De Leon J see Perez-Rodriguez MM
Dell'Osso B, Hadley SJ, Allen A, Baker B, Chaplin WF, Hollander E. Escitalopram in the treatment of impulsive-compulsive Internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. Mar 452–456
Demeter C see Youngstrom EA
Demirtas-Tatlidede A, Mechanic-Hamilton D, Press DZ, Pearlman C, Stern WM, Thall M, Pascual-Leone A. Open-label, prospective study of repetitive transcranial magnetic stimulation (rTMS) in the long-term treatment of refractory depression: reproducibility and duration of the antidepressant effect in medication-free patients. June 930–934
Demitrack MA see Avery DH; Janicak PG
Deng L see Yu H
Dennehy EB see Marangell LB
de Oliveira RV see Bisol LW
Desaiah D see Perahia DGS
de Souza SE see Bisol LW
Detke MJ see Kornstein SG
Dew MA see Karp JF
de Zoysa N see Patel MX
de Zwaan M see Mueller A
Diaz-Sastre C see Perez-Rodriguez MM
Di Lorenzo G see Leo R
Dilsaver SC, Benazzi F. Diagnosing depressive mixed states in bipolar disorders. July e19
Dilsaver SC, Benazzi F. Treating depressive mixed states in bipolar disorders. Aug e23
Dimopoulos NP see Mitsonis CI
Dittmann S, Seemüller F, Grunze HC, Schwarz MJ, Zach J, Fast K, Born C, Dargel S, Engel RR, Bernhard B, Möller H-J, Riedel M, Severus WE. Impact of homocysteine levels on cognition in euthymic bipolar patients: a cross-sectional study. June 899–906
Djokovic M see Nejtek VA
Dolan CR see Biederman J
Dong Q see Ciraulo DA
Doraiswamy PM see Henderson DC
Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. Dec 1901–1915
Dowd S see Rado JT
Doyle AE see Biederman J
Drevets WC see Bonne O
Duff K see Beglinger LJ
Dunner DL, Thase ME. Reply to Benazzi F: Misdiagnosis of bipolar II disorder as major depressive disorder [letter]. Mar 501–503
Dunner DL see Kornstein SG
Eerdekens M see Meltzer HY
Efron LA see Chronis-Tuscano A
Elhai JD, Grubaugh AL, Kashdan TB, Frueh BC. Empirical examination of a proposed refinement to DSM-IV posttraumatic stress disorder symptom criteria using the National Comorbidity Survey replication data. Apr 597–602. Correction, Dec 1985
Elhaj O see Gao K
Elias A see Antony JT
Ellis PM see Palmer SE
Ellis SP see Mann JJ
Elter JR see Calhoun PS
Emslie GJ see Croarkin PE
Endicott J see Gelenberg AJ
Eng SM see Strom BL
Engel RR see Dittmann S
Engeland A see Bramness JG
Enns MW see Bolton JM
Erath M see Weinmann S
Ereshefsky L see Scharf M
Erickson CA see McDougle CJ
Eronen M see Joffe G
Ertugrul A see Meltzer HY
Eser D see Baghai TC
Esposito-Smythers C see Goldstein BI
Evins AE, Goff DC. Varenicline treatment for smokers with schizophrenia: a case series [letter]. June 1016
Evins AE see Culhane MA; Loebl T
Fabian TJ see Coley KC
Fagiolini A. Medical monitoring in patients with bipolar disorder: a review of data. June e16
Fagiolini A, Frank E, Turkin S, Houck PR, Soreca I, Kupfer DJ. Metabolic syndrome in patients with bipolar disorder [letter]. Apr 678–679
Fagiolini A see Fleet-Michaliszyn SB; Salvi V
Faich GA see Strom BL
Fallu A see Ravindran AV
Fan AH, Hassell J. Bipolar disorder and comorbid personality psychopathology: a review of the literature. Nov 1794–1803
Faraone SV see Biederman J; Robison RJ
Farfel GM see Friedman MJ
Faries D see Ascher-Svanum H
Fast K see Dittmann S
Fava M see Gelenberg AJ; Gilmer WS; McGrath PJ; Mischoulon D; Papakostas GI; Perahia DGS; Trivedi MH
Fazel S, Cartwright J, Norman-Nott A, Hawton K. Suicide in prisoners: a systematic review of risk factors. Nov 1721–1731
Fecteau S see Fregni F
Felde A see Daniels JP
Feldman N see Scharf M
Feusner J see Bystritsky A
Feusner JD see Bystritsky A
Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. Suppl 4, 9–14
Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, and Pratt RD. Randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. Jan 149–159. Correction, Feb 329
Findling RL see Gao K; Youngstrom EA
Fink M see Husain MM; McClintock SM
Fischer G see Marangell LB
Fischer JH see Miller LJ
Fleck J see Gilmer WS
Fleet-Michaliszyn SB, Soreca I, Otto AD, Jakicic JM, Fagiolini A, Kupfer DJ, Goodpaster DJ. Prospective observational study of obesity, body composition, and insulin resistance in 18 women with bipolar disorder and 17 matched control subjects. Dec 1892–1900
Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, Maj M, McIntyre RS, Naber D, Newcomer JW, Olfson M, Ösby U, Sartorius N, Lieberman JA. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. Apr 514–519
Flicker L see Ford AH
Flint AJ see Rothschild AJ
Flory JD see Miller CJ
Foa EB see Simon NM
Fong SYY see Lam SP
Fontenelle LF, Araújo Leite MA. Treatment-resistant self-mutilation, tics, and obsessive-compulsive disorder in neuroacanthocytosis: a mouth guard as a therapeutic approach [letter]. July 1186–1187
Ford AH, Flicker L, Thomas J, Norman P, Jamrozik K, Almeida OP. Vitamins B_{12}, B_6, and folic acid for onset of depressive symptoms in older men: results from a 2-year placebo-controlled randomized trial. Aug 1203–1209
Ford CV. Review of Woolfolk RL, Allen LA: *Treating Somatization: A Cognitive-Behavioral Approach*. Jan 168
Fortinsky PM see Steinberg EM
Fraguas D, Merchán-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, Cifuentes A, Giráldez M, Arango C. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. July 1166–1175
Fraguas D see Villero S
Francione-Witt C see Zimmerman M
Frank E see Fagiolini A; Salvi V
Fratoni S see Rothschild AJ
Frazier TW see Youngstrom EA

Freeman AM III. Review of Brendel DH: *Healing Psychiatry: Bridging the Sciences/Humanism Divide*. Apr 683–684
Freeman MP. Academic psychiatry: the effects of gravity on career trajectory [commentary]. Nov 1791–1792
Freeman MP. Clinical trials and tribulations: perspectives on research career development. Mar 470–471
Freeman MP. Mentorship: the genuine article. Aug 1297
Freeman MP. Perinatal psychiatry: risk factors, treatment data, and specific challenges for clinical researchers. Apr 633–634
Freeman MP. Reproductive neuroscience: biology, environment, and clinical implications in women's mental health. June 971–972
Freeman MP. This month's selections. Nov 1790–1791
Freeman MP see Gelenberg AJ
Fregni F, Liguori P, Fecteau S, Nitsche MA, Pascual-Leone A, Boggio PS. Cortical stimulation of the prefrontal cortex with transcranial direct current stimulation reduces cue-provoked smoking craving: a randomized, sham-controlled study. Jan 32–40
Freudenreich O see Culhane MA
Freyberger HJ see Spitzer C
Fric M see Brunnauer A
Fried R see Biederman J
Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Reply to Hussain HM: Comments on a randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting [letter]. Apr 680–681
Frueh BC see Elhai JD
Frye MA. Diagnostic dilemmas and clinical correlates of mixed states in bipolar disorder. May e13
Frytak JR see Stensland MD
Furukawa TA see Cipriani A; Watanabe N
Gabriele M see Rothschild AJ
Gaebel W see Weinmann S
Gajwani P see Gao K
Galbaud du Fort G see Rahme E
Gallop RJ see Linehan MM
Ganadjian K see Zisook S
Ganguli R see Coley KC
Ganocy SJ see Gao K
Gao K, Ganocy SJ, Gajwani P, Muzina DJ, Kemp DE, Calabrese JR. Review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. Feb 302–309
Gao K, Verduin ML, Kemp DE, Tolliver BK, Ganocy SJ, Elhaj O, Bilali S, Brady KT, Findling RL, Calabrese JR. Clinical correlates of patients with rapid-cycling bipolar disorder and a recent history of substance use disorder: a subtype comparison from baseline data of 2 randomized, placebo-controlled trials. July 1057–1063
Garcia C see Huey ED
Garcia-Resa E see Perez-Rodriguez MM
Garlow SJ. Interventions for acute mood episodes in patients with bipolar disorder. Feb e05
Garno JL see Goldberg JF
Garza M see Brown ES
Gastfriend DR see Ciraulo DA
Gau SS-F, Chen S-J, Chou W-J, Cheng H, Tang C-S, Chang H-L, Tzang R-F, Wu Y-Y, Huang Y-F, Chou M-C, Liang H-Y, Hsu Y-C, Lu H-H, Huang Y-S. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Jan 131–140
Gauvin L see Richardson J; Steiger H
Geddes JR see Cipriani A
Gelenberg AJ. Search for knowledge: developing the American Psychiatric Association's Practice Guideline for Major Depressive Disorder [ASCP Corner]. Oct 1658–1659
Gelenberg AJ, Freeman MP. Thanks to JCP peer reviewers [editorial]. Jan 7–11
Gelenberg AJ, Thase ME, Meyer RE, Goodwin FK, Katz MM, Kraemer HC, Potter WZ, Shelton RC, Fava M, Khan A, Trivedi MH, Ninan PT, Mann JJ, Bergeson S, Endicott J, Kocsis JH, Leon AC, Manji HK, Rosenbaum JF. History and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. Oct 1513–1528. Correction, Dec 1985
Geller SE see Miller LJ
Gendron A see Mamo DC
Gentil V. Introduction to bipolar disorder and comorbid conditions. Jan e01
Gentile S. Infant safety with antipsychotic therapy in breast-feeding: a systematic review. Apr 666–673
George MS see Avery DH
Ghaemi SN see Rakofsky JJ
Gill MK see Goldstein BI
Gilmer WS, Gollan JK, Wisniewski SR, Howland RH, Trivedi MH, Miyahara S, Fleck J, Thase ME, Alpert JE, Nierenberg AA, Warden D, Fava M, Rush AJ. Does the duration of index episode affect the treatment outcome of major depressive disorder? a STAR*D report. Aug 1246–1256
Giráldez M see Fraguas D
Glass JM. Fibromyalgia and cognition. Suppl 2, 20–24
Glass JM see Arnold LM
Glazer WM see Arnold LM
Glenn T see Berghöfer A
Glick ID, Poyurovsky M, Ivanova O, Koran LM. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. Dec 1856–1859
Glick ID, Siris SG, Davis JM. Treating schizophrenia with comorbid depressive or demoralization symptoms [letter]. Mar 501
Godleski LS. Review of Simon RI, Hales RE (eds): *The American Psychiatric Publishing Textbook of Suicide Assessment and Management*. Oct 1664
Goetz RR see Aaronson CJ
Goff DC see Culhane MA; Evins AE
Goikolea JM see Martinez-Aran A
Gold J see Ciranni M
Goldberg JF. Optimizing treatment outcomes in bipolar disorder under ordinary conditions. Suppl 3, 11–19
Goldberg JF. What constitutes evidence-based pharmacotherapy for bipolar disorder? part 2: complex presentations and clinical context [ASCP Corner]. Mar 495–496
Goldberg JF. Whither the academic psychiatrist? [editorial] Nov 1792–1793
Goldberg JF, Garno JL, Callahan AM, Kearns DL, Kerner B, Ackerman SH. Overdiagnosis of bipolar disorder among substance use disorder inpatients with mood instability. Nov 1751–1757
Goldberg JF see Nowakowska C
Goldenberg DL. Introduction: fibromyalgia and its related disorders. Suppl 2, 4–5
Goldenberg DL. Multidisciplinary modalities in the treatment of fibromyalgia. Suppl 2, 30–34
Goldenberg DL see Arnold LM
Goldstein BI, Birmaher B, Axelson DA, Goldstein TR, Esposito-Smythers C, Strober MA, Hunt J, Leonard H, Gill MK, Iyengar S, Grimm C, Yang M, Ryan ND, Keller MB. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. Dec 1953–1959
Goldstein J see Mamo DC
Goldstein MR see Mascitelli L
Goldstein RB, Dawson DA, Chou SP, Ruan WJ, Saha TD, Pickering RP, Stinson FS, Grant BF. Antisocial behavioral syndromes and past-year physical health among adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Mar 368–380
Goldstein RB see Grant BF; Pulay AJ; Stinson FS
Goldstein TR see Goldstein BI
Gollan JK see Gilmer WS
Gonda X see Rihmer Z
Gonzalez R, Bernstein I, Suppes T. An investigation of water lithium concentrations and rates of violent acts in 11 Texas counties: can an association be easily shown? [letter] Feb 325–326
González-Pinto A, Vega P, Ibáñez B, Mosquera F, Barbeito S, Gutiérrez M, Ruiz de Azúa S, Ruiz I, Vieta E. Impact of cannabis and other drugs on age at onset of psychosis. Aug 1210–1216
Goodale EP see Papakostas GI
Goodman DW see Adler LA
Goodpaster BH see Fleet-Michaliszyn SB
Goodwin FK see Gelenberg AJ
Goodwin GM see Tohen M
Goodwin RD see Blanco C
Gordon JS, Staples JL, Blyta A, Bytyqi M, Wilson AT. Treatment of posttraumatic stress disorder in postwar Kosovar adolescents using mind-body skills groups: a randomized controlled trial. Sept 1469–1476
Gorenflo DW see Schwenk TL
Gorman JM see Aaronson CJ
Goto H see Honda T

Grabe HJ see Spitzer C
Grafman J see Huey ED
Grant BF, Chou SP, Goldstein RB, Huang B, Stinson FS, Saha TD, Smith SM, Dawson DA, Pulay AJ, Pickering RP, Ruan WJ. Prevalence, correlates, disability, and comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. Apr 533–545
Grant BF see Goldstein RB; Hasin DS; Hatzenbuehler ML; Pulay AJ; Stinson FS
Grant JE, Kim SW, Hartman BK. Double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. May 783–789
Grecu-Gabos I see Tohen M
Greenhill L see Brodsky BS
Greist JH. Review of Marks IM, Cavanagh K, Gega L: *Hands-On Help: Computer-Aided Psychotherapy*. Aug 1341
Greist JH see Kornstein SG
Griffith JM, Hasley JP, Severn DG. Measurement of pain and medication effect in a study of duloxetine [letter]. June 1022
Grimm C see Goldstein BI
Grinshpoon A see Mirsky J
Grof P see Berghöfer A
Groleau P see Steiger H
Grossberg GT see Salzman C
Grover S see Bharadwaj R
Grubaugh AL see Elhai JD
Gründer G see Paulzen M
Grunze H see Hegerl U
Grunze HC see Dittmann S
Gu H see Perkins DO
Gualtieri CT, Morgan DW. Frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials. July 1122–1130
Gur RE see Satterthwaite TD
Gutiérrez M see González-Pinto A
Gutierrez SN see Zajecka JM
Gutterman EM see Blonde L
Ha K see Kim J-H
Haas GL see Mann JJ
Hadley SJ see Dell'Osso B
Häfner S see Baghai TC
Hakkaart-van Roijen L see Soeteman DI
Hakko H see Joffe G
Hales DJ see Rapaport MH
Halperin JM see Miller CJ
Hamamura T, Kodama M, Harada T. Intrinsic activity of aripiprazole is not 30% of dopamine, but only about 6% under ideal antipsychotic therapy [letter with reply]. May 863–865
Hamann J, Leucht S, Kissling W. Reply to Preda A: Shared decision making in schizophrenia treatment [letter]. Feb 326–327
Hamer AM see Hartung DM
Hamer RM see Perkins DO
Hanssens L see Blonde L; van Winkel R
Haq N see Steinberg EM
Harada T see Hamamura T
Harkavy-Friedman JM see Sher L
Harms SE see Recupero PR
Harrison-Woolrych M see Palmer SE
Hartman BK see Grant JE
Hartung DM, Wisdom JP, Pollack DA, Hamer AM, Haxby DG, Middleton L, McFarland BH. Patterns of atypical antipsychotic subtherapeutic dosing among Oregon Medicaid patients. Oct 1540–1547
Harty SC see Miller CJ
Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BF. Cannabis withdrawal in the United States: results from NESARC. Sept 1354–1363
Hasin DS see Blanco C; Hatzenbuehler ML; Pulay AJ; Vesga-López O
Hasley JP see Griffith JM
Hassell J see Fan AH
Hatzenbuehler ML, Keyes KM, Narrow WE, Grant BF, Hasin DS. Racial/ethnic disparities in service utilization for individuals with co-occurring mental health and substance use disorders in the general population: results from the National Epidemiologic Survey on Alcohol and Related Conditions. July 1112–1121
Hauser P see Nelligan JA
Hawton K see Fazel S
Haxby DG see Hartung DM
Hayashi K see Honda T
Hays RW see Sajatovic M
Heart KL see Janicak PG
Heath AC see Yonkers KA
Heatlie HF see Abel KM
Hecker JE see Higgins DM
Heckers S. Review of Williamson P: *Mind, Brain, and Schizophrenia*. June 1024–1025
Heekin MH see Rothbaum BO
Hegerl U, Bottner A-C, Holtschmidt-Täschner B, Born C, Seemüller F, Scheunemann W, Schütze M, Grunze H, Henkel V, Mergl R, Angst J. Onset of depressive episodes is faster in patients with bipolar versus unipolar depressive disorder: evidence from a retrospective comparative study. July 1075–1080
Heijnen WTC, van den Broek WW, Birkenhäger TK. Treatment failure with a tricyclic antidepressant followed by lithium addition and response to subsequent electroconvulsive therapy. Dec 1887–1891
Heilä H see Karlsson L
Heimberg RG see Vesga-López O
Helsel JC see Sit DK
Henderson DC. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics. Feb e04
Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. Suppl 1, 32–44
Henkel V see Hegerl U
Hennekens CH see Fleischhacker WW
Heo M see Rothschild AJ
Hermisson I see Brunnauer A
Hernandez V, Tsuang JW. Review of Crossley N: *Contesting Psychiatry: Social Movements in Mental Health*. Nov 1837
Hides L see Mathias S
Higgins DM, Hecker JE. Randomized trial of brief cognitive-behavioral therapy for prevention of generalized anxiety disorder [letter]. Aug 1336
Ho CKW see Lam SP
Hoerger S see Weinmann S
Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. Apr 621–632
Holi M see Karlsson L
Hollandbeck MS see Kornstein SG
Hollander E see Dell'Osso B; Trivedi MH
Holma IAK see Holma KM
Holma KM, Holma IAK, Melartin TK, Rytsälä HJ, Isometsä ET. Long-term outcome of major depressive disorder in psychiatric patients is variable. Feb 196–205
Holma KM, Melartin TK, Holma IAK, Isometsä ET. Predictors for switch from unipolar major depressive disorder to bipolar disorder type I or II: a 5-year prospective study. Aug 1267–1275
Holtschmidt-Täschner B see Hegerl U
Honda T, Katano Y, Toyoda H, Hayashi K, Ishigami M, Nakano I, Goto H, Yamamoto K, Takamatsu J. Effect of ribavirin, in combination with interferon in patients with hepatitis C, on the bleeding risk associated with selective serotonin reuptake inhibitors [letter]. Apr 679–680
Hopko DR see Daughters SB
Horrigan JP see Bielski RJ
Horwitz MB see Petersen TJ
Houck PR see Fagiolini A
Hough D see Meltzer HY
Howard H see Richardson J
Howard LM see Abel KM
Howell HB see Yonkers KA
Howland RH see Gilmer WS
Hsu Y-C see Gau SS-F
Huang B see Grant BF; Pulay AJ; Stinson FS
Huang C-C see Yeh Y-W
Huang C-L see Su K-P
Huang JO see Steiner M
Huang K-C see Su K-P
Huang K-L see Loebl T
Huang S-Y see Su K-P
Huang Y-F see Gau SS-F
Huang Y-S see Gau SS-F
Hudak R see Kondziolka D
Hudson JI see Javaras KN
Hudson TJ, Owen RR, Thrush CR, Armitage TL, Thapa P. Guideline implementation and patient-tailoring strategies to improve medication adherence for schizophrenia. Jan 74–80
Huey ED, Garcia C, Wassermann EM, Tierney MC, Grafman J. Stimulant treatment of frontotemporal dementia in 8 patients [letter]. Dec 1981–1982
Huffman JC see Petersen TJ
Hull S see Scharf M
Hunt J see Goldstein BI
Hurwitz TD see Khawaja IS

Husain MM, McClintock SM, Rush AJ, Knapp RG, Fink M, Rummans TA, Rasmussen K, Claassen C, Petrides G, Biggs MM, Mueller M, Sampson S, Bailine SH, Lisanby SH, Kellner CH. Efficacy of acute electroconvulsive therapy in atypical depression. Mar 406–411
Husain MM see Janicak PG; McClintock SM
Hussain HM. Comments on a randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting [letter with reply]. Apr 680–681
Hynan LS see Brandon AR; Weiner MF
Iacoboni M see Bystritsky A
Ibáñez B see González-Pinto A
Ignacio RV see Sajatovic M
Inagaki M see Bonne O
Iribarren MM see Rubio G
Irimia V see Dossenbach M
Isenberg KE see Avery DH
Ishigami M see Honda T
Ishihara T see Ujike H
Isometsä ET see Holma KM
Israel M see Richardson J; Steiger H
Ivanova O see Glick ID
Iyengar S see Goldstein BI
Jackson WC. Importance of facilitating adherence in maintenance therapy for bipolar disorder. Jan e03
Jain R. Managing bipolar disorder from urgent situations to maintenance therapy. Mar e07
Jain R. Pain and the brain: diabetic neuropathic pain. Aug e22
Jain R see Arnold LM
Jakic JM see Fleet-Michaliszyn SB
Jamrozik K see Ford AH
Janicak PG, O'Reardon JP, Sampson SM, Husain MM, Lisanby SH, Rado JT, Heart KL, Demitrack MA. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. Feb 222–232
Janicak PG see Avery DH; Rado JT
Jarvik L see Salzman C
Javaras KN, Pope HG Jr, Lalonde JK, Roberts JL, Nillni YI, Laird NM, Bulik CM, Crow SJ, McElroy SL, Walsh BT, Tsuang MT, Rosenthal NR, Hudson JI. Co-occurrence of binge eating disorder with psychiatric and medical disorders. Feb 266–273
Jayathilake K see Meltzer HY
Jefferson JW. Strategies for switching antidepressants to achieve maximum efficacy. Suppl E1, 14–18
Jefferson JW. Who put the tyramine in Mrs. Murphy's fava bean? [letter] Aug 1336–1337
Jensen PS. Role of psychosocial therapies in managing aggression in children and adolescents. Suppl 4, 37–42
Jeste DV see Salzman C
Jiles CD see Chronis-Tuscano A
Jiménez M see Rubio G
Jiménez-Arriero MA see Rubio G
Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, Eronen M, Räsänen P. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. May 706–711
John U see Spitzer C
Johnson BA. Review of Ruiz P, Strain EC, Langrod JG: *The Substance Abuse Handbook.* Nov 1837–1838
Johnson SL see Miller IW
Johnston MV. Review of Moldin SO, Rubenstein JLR (eds): *Understanding Autism: From Basic Neuroscience to Treatment.* Dec 1986–1987
Jokelainen J see Koponen H
Jones ER Jr see Calhoun PS
Jones HA see Chronis-Tuscano A
Joober R see Richardson J; Steiger H
Jureidini J, Mintzes B. Does venlafaxine maintenance therapy prevent depression recurrences or drug discontinuation reactions? [letter with reply] May 865–866
Juva K see Muhonen LH
Kaehler L see McElroy SL
Kaiser K see Nejtek VA
Kaiser R see Biederman J
Kan HJ see Blonde L
Kane JM. Evidence-based strategy for remission in schizophrenia. Suppl 3, 25–30
Kane JM. Relapse prevention in patients with schizophrenia. Apr e11
Kane JM. Sedation as a side effect of the treatment of mental disorders. July e20
Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. Suppl 1, 18–31
Kane JM see Correll CU; Strom BL
Kang UG see Chang JS
Kapczinski F see Machado-Vieira R
Kaplan JT see Bystritsky A
Kapoor S. Transcranial magnetic stimulation: clinical applications beyond depression [letter with reply]. July 1191–1192
Kapur S see Mamo DC; Uchida H
Karaiskos D see Paparrigopoulos T
Kararizou EG see Mitsonis CI
Karlsson L, Kiviruusu O, Miettunen J, Heilä H, Holi M, Ruuttu T, Tuisku V, Pelkonen M, Marttunen M. One-year course and predictors of outcome of adolescent depression: a case-control study in Finland. May 844–853
Karp JF, Whyte EM, Lenze EJ, Dew MA, Begley A, Miller MD, Reynolds CF III. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability. Mar 457–463
Karsz FR, Vance A, Anderson VA, Brann PG, Wood SJ, Pantelis C, Brewer WJ. Olfactory impairments in child attention-deficit/hyperactivity disorder. Sept 1462–1468
Kasapinovic S see Rothschild AJ
Kashdan TB see Elhai JD
Kashima H see Kishimoto T
Katano Y see Honda T
Katsanou M-NE see Mitsonis CI
Katz MM see Gelenberg AJ
Kauer-Sant'Anna M see Bond DJ
Kaymaz N, van Os J, Loonen AJM, Nolen WA. Evidence that patients with single versus recurrent depressive episodes are differentially sensitive to treatment discontinuation: a meta-analysis of placebo-controlled randomized trials. Sept 1423–1436
Kearns DL see Goldberg JF
Keck PE Jr see McElroy SL
Keinänen-Kiukaanniemi S see Koponen H
Keitner GI see Miller IW
Kelle» MB, Kocsis JH. Reply to Jureidini J: Does venlafaxine maintenance therapy prevent depression recurrences or drug discontinuation reactions? [letter] May 865–866
Keller MB see Goldstein BI
Kellner CH see Husain MM; McClintock SM
Kemp DE see Gao K
Kenan J. Review of Bernet W, Ash DR: *Children of Divorce: A Practical Guide for Parents, Therapists, Attorneys, and Judges, 2nd ed.* July 1193–1194
Kenealy DC see Biederman J
Kennedy SH see Ravindran AV
Kerner B see Goldberg JF
Kerr M see Berger GE
Kerselaers W see Newcomer JW
Kerwin LE see Bystritsky A
Ketter TA. Incorporating trial data into bipolar disorder management. July e21
Ketter TA. Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. Suppl 5, 9–15
Ketter TA see Nowakowska C
Keyes KM see Hasin DS; Hatzenbuehler ML
Khan A, Bhat A. Is the problem of a high placebo response unique to antidepressant trials? [ASCP Corner] Dec 1979–1980
Khan A see Gelenberg AJ; Nelson JC
Khan AY see McGrath PJ
Khawaja IS, Hurwitz TD, Schenck CH. Violent parasomnia associated with a selective serotonin reuptake inhibitor: a case report [letter]. Dec 1982–1983
Kilian R see Weinmann S
Killeen TK see Rothbaum BO
Kim E see Coley KC
Kim J-H, Choi SS, Ha K. Closer look at depression in mothers who kill their children: is it unipolar or bipolar depression? Oct 1625–1631
Kim MS see Blonde L; Coley KC
Kim SH see Chang JS
Kim SW see Grant JE
Kim YS see Chang JS
Kingma EM see van Duijn E
Kinon BJ see Ascher-Svanum H
Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. Mar 385–391
Kiviruusu O see Karlsson L
Kleber RJ see Alisic E
Knapp RG see Husain MM; McClintock SM

Knowler WC see Sahota PKC
Kocsis JH see Gelenberg AJ; Keller MB
Kodama M see Hamamura T; Ujike H
Kohn R see Mirsky J
Kolko D see Brodsky BS
Kollins SH see Adler LA
Kondziolka D, Hudak R. Management of obsessive-compulsive disorder–related skin picking with gamma knife radiosurgical anterior capsulotomies: a case report [letter]. Aug 1337–1340
Koponen H, Jokelainen J, Keinänen-Kiukaanniemi S, Kumpusalo E, Vanhala M. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. Feb 178–182
Koran LM see Glick ID
Koren G see Azoulay L
Kornstein SG, Dunner DL, Meyers AL, Whitmyer VG, Mallinckrodt CH, Wohlreich MM, Detke MJ, Hollandbeck MS, Greist JH. Randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. Sept 1383–1392
Kotaka T see Ujike H
Kotler M see Dossenbach M
Kraemer HC see Gelenberg AJ; Salzman C
Kramer JH see Rankin KP
Kramer M see Meltzer HY
Krishen A see Papakostas GI
Krishnan S see Adler LA
Krulewicz S see Simon NM
Kryzhanovskaya L see Tohen M
Kudler H see Calhoun PS
Kumar A. Review of Blazer DG, Steffens DC, Busse EW (eds): *American Psychiatric Publishing Textbook of Geriatric Psychiatry, 3rd ed.* Oct 1664–1665
Kumar A. Review of Blazer DG, Steffens DC, Busse EW (eds): *Essentials of Geriatric Psychiatry.* Oct 1664–1665
Kumpusalo E see Koponen H
Kuperman S see Pike SK
Kupfer DJ see Fagiolini A; Fleet-Michaliszyn SB
Kuroda S see Ujike H
Kwon JS see Lee SJ
Labat DB see Brandon AR
Labelle A see Uchida H
Laird NM see Javaras KN
Laita P see Fraguas D
Lalonde JK see Javaras KN
Lam RW see Bond DJ
Lam SP, Fong SYY, Ho CKW, Yu MWM, Wing YK. Parasomnia among psychiatric outpatients: a clinical, epidemiologic, cross-sectional study. Sept 1374–1382
Lambert M see Fleischhacker WW
Lambert T see Lauriello J
Landgraf JM see Spencer TJ
Lane H-Y see Lin C-H; Lin Y-C
Lane R see Meltzer HY
Lang AJ see Simon NM
Langbehn DR see Beglinger LJ
Lankford A see Scharf M
Lara DR see Bisol LW; Machado-Vieira R
Larkin GL see Smith RP
Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. May 790–799
Laursen TM, Munk-Olsen T, Nordentoft M, Mortensen PB. Reply to Benazzi F: Continuum hypothesis of mood disorders [letter]. July 1187–1188
Laux G see Brunnauer A
Lavretsky H. Review of Hughes JC, Louw SJ, Sabat SR (eds): *Dementia: Mind, Meaning, and the Person.* Aug 1343
Law MR, Soumerai SB, Ross-Degnan D, Adams AS. Longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. Jan 47–53
Lawrie SM see Taylor M
LeBeau RT see Simon NM
Lebowitz BD see Salzman C
Leckman JF. Review of Harris JC: *Intellectual Disability: Understanding Its Development, Causes, Classification, Evaluation, and Treatment.* July 1193
Lee KY see Chang JS
Lee SH see Loebl T
Lee SJ, Choi EJ, Kwon JS. Naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder. Apr 555–562
Leja LM see Schwenk TL
Lejuez CW see Daughters SB
LeLorier J see Azoulay L
LeMelledo J-M see Steiner M
Lenze EJ see Karp JF
Leo R, Razzini C, Di Lorenzo G, Bianchi F, Tesauro M, Zanasi M, Siracusano A, Romeo F. Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol [letter]. Feb 327–328
Leon AC see Gelenberg AJ
Leonard H see Goldstein BI
Leucht S see Fleischhacker WW
Levav I see Mirsky J
Li X see Reeves H
Liang H-Y see Gau SS-F
Liappas J see Paparrigopoulos T
Lieberman JA see Fleischhacker WW; Perkins DO
Liebowitz MR see Blanco C
Liguori P see Fregni F
Lin C-H, Lin K-S, Lin C-Y, Chen M-C, Lane H-Y. Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine. Jan 54–59
Lin C-Y see Lin C-H
Lin D see Lauriello J
Lin H see Yonkers KA
Lin J-J, Lu T-H. High-risk groups for charcoal-burning suicide in Taiwan, 2001–2005 [letter]. Sept 1499–1501
Lin K-S see Lin C-H
Lin Y-C, Chen H-Z, Chang T-J, Lane H-Y. Hypokalemia following rapid titration of quetiapine treatment [letter]. Jan 165–166
Lindenmayer J-P. Reply to Murphy BP: Inconclusive evidence for the efficacy of olanzapine in the treatment of negative symptoms in schizophrenia [letter]. Jan 164–165
Lindenmayer J-P see Ciranni M
Linehan MM, McDavid JD, Brown MZ, Sayrs JHR, Gallop RJ. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. June 999–1005
Linke AM see Nelligan JA
Lisanby SH see Avery DH; Husain MM; Janicak PG; McClintock SM
L'Italien GJ see Blonde L; Newcomer JW
Liu S-M see Vesga-López O
Liu X see Mann JJ
Lizardi D see Sher L
Loebl T, Angarita GA, Pachas GN, Huang K-L, Lee SH, Nino J, Logvinenko T, Culhane MA, Evins AE. Randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. Mar 480–486
Loft H see Wilcock GK
Loftis JM see Nelligan JA
Logozar-Perkovic D see Dossenbach M
Logvinenko T see Loebl T
Londborg PD see Bielski RJ
Lönnqvist J see Muhonen LH
Loo C see Avery DH
Looker HC see Sahota PKC
Loonen AJM see Kaymaz N
López FA see Findling RL
Lowry AJ see Dossenbach M
Lu H-H see Gau SS-F
Lu T-H see Lin J-J
Lubman D see Berger GE
Lubman DI see Mathias S
Luby JL, Belden AC. Clinical characteristics of bipolar vs. unipolar depression in preschool children: an empirical investigation. Dec 1960–1969
Luckenbaugh DA see Bonne O; Machado-Vieira R
Lydiard RB see Mellman T
Lyon GJ, Coffey BJ. Review of Barkley RA: *Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 3rd ed.* June 1023
Machado-Vieira R, Salvadore G, Luckenbaugh DA, Manji HK, Zarate CA Jr. Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. June 946–958
Machado-Vieira R, Soares JC, Lara DR, Luckenbaugh DA, Busnello JV, Marca G, Cunha A, Souza DO, Zarate CA Jr, Kapczinski F. Double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. Aug 1237–1245
Macmillan C see Miller LJ

Mago R, Chism LM, Pinninti NR, Certa K. Urinary retention associated with ziprasidone: a case report [letter]. Mar 499–500
Maina G, Albert U, Rosso G, Bogetto F. Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study. Apr 609–616
Maina G see Salvi V
Maixner DF see Avery DH
Maj M see Fleischhacker WW
Makita K see Kishimoto T
Malaspina D see Anglin DM
Mallinckrodt CH see Kornstein SG
Malone KM see Mann JJ
Maloney MJ. Review of Palombo J: *Nonverbal Learning Disabilities: A Clinical Perspective*. May 870
Malvini L see Cipriani A
Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, Kapur S. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. Jan 81–86
Mamo DC see Uchida H
MANGA Study Group see Cipriani A
Manji HK see Gelenberg AJ; Machado-Vieira R
Manlosa NB see Shiovitz TM
Mann JJ, Ellis SP, Waternaux CM, Liu X, Oquendo MA, Malone KM, Brodsky BS, Haas GL, Currier D. Classification trees distinguish suicide attempters in major psychiatric disorders: a model of clinical decision making. Jan 23–31
Mann JJ see Brodsky BS; Gelenberg AJ; Sher L
Mann SW see Uchida H
Mannaert EJL see Uchida H
Manu P see Correll CU
Manzanares J see Rubio G
Marangell LB, Dennehy EB, Wisniewski SR, Bauer MS, Miyahara S, Allen MH, Martinez M, Al Jurdi RK, Thase ME. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD. June 916–922
Marangell LB, Suppes T, Zboyan HA, Prashad SJ, Fischer G, Snow D, Sureddi S, Allen JC Jr. 1-year pilot study of vagus nerve stimulation in treatment-resistant rapid-cycling bipolar disorder. Feb 183–189
Marangell LB see Nowakowska C
Marca G see Machado-Vieira R
Marchant BK see Robison RJ
Marcus RN see Newcomer JW; Trivedi MH
Marcus SC see Olfson M
Marder SR. Treatment of agitation in patients with schizophrenia. June e17
Markulev C see Berger GE
Marmar CR see Friedman MJ
Martínez I see Rubio G
Martinez M see Marangell LB
Martinez-Aran A, Torrent C, Tabares-Seisdedos R, Salamero M, Daban C, Balanza-Martinez V, Sanchez-Moreno J, Goikolea JM, Benabarre A, Colom F, Vieta E. Neurocognitive impairment in bipolar patients with and without history of psychosis. Feb 233–239
Martínez-Arán A see Mur M
Marttunen M see Karlsson L
Mascitelli L, Pezzetta F, Goldstein MR. Is statin use safe in individuals with psychotic disorders? [letter] Sept 1499
Maslow K see Salzman C
Mathias S, Lubman DI, Hides L. Substance-induced psychosis: a diagnostic conundrum. Mar 358–367
Mattes JA. High-dose olanzapine versus clozapine [letter with reply]. Oct 1660–1661
Mattes JA. Levetiracetam in patients with impulsive aggression: a double-blind, placebo-controlled trial. Feb 310–315
Matthews AM see Nelligan JA
Mauri M, Rucci P, Calderone A, Santini F, Oppo A, Romano A, Rinaldi S, Armani A, Polini M, Pinchera A, Cassano GB. Axis I and II disorders and quality of life in bariatric surgery candidates. Feb 295–301
Mauri M see Borri C
May RS see Reeves H
Mayes TL see Croarkin PE
Mayleben D see Scharf M
McClintock SM, Husain MM, Rush AJ, Claassen C, Biggs MM, Knapp RG, Mueller M, Fink M, Bailine SH, Rummans TA, Sampson S, Petrides G, Kellner CH, Lisanby SH. Reply to Swartz CM: ECT not proven for atypical depression [letter]. Oct 1662–1663
McClintock SM see Husain MM
McConchie M see Berger GE
McDavid JD see Linehan MM
McDonnell D see Lauriello J
McDougle CJ, Stigler KA, Erickson CA, Posey DJ. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. Suppl 4, 15–20
McElroy SL. Understanding the complexity of bipolar mixed episodes. Feb e06
McElroy SL, Nelson EB, Welge JA, Kaehler L, Keck PE Jr. Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial. Mar 433–440
McElroy SL see Javaras KN
McEvoy JP. Functional outcomes in schizophrenia. Suppl 3, 20–24
McEvoy JP see Perkins DO
McFarland BH see Hartung DM
McFarlane AC see Bryant RA
McGirr A, Renaud J, Séguin M, Alda M, Turecki G. Course of major depressive disorder and suicide outcome: a psychological autopsy study. June 966–970
McGlinchey JB see Zimmerman M
McGorry PD see Berger GE
McGrath PJ, Khan AY, Trivedi MH, Stewart JW, Morris DW, Wisniewski SR, Miyahara S, Nierenberg AA, Fava M, Rush AJ. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. Dec 1847–1855
McGuire H see Cipriani A; Watanabe N
McIntyre RS. Acute treatment of patients with bipolar mixed episodes. Apr e10
McIntyre RS see Fleischhacker WW
McLean RM see Palmer SE
McQuade RD see Blonde L; Newcomer JW
Mechanic-Hamilton D see Demirtas-Tatlidede A
Meissner WW. Review of Cooper AM (ed): *Contemporary Psychoanalysis in America: Leading Analysts Present Their Work*. Mar 504–505
Melartin TK see Holma KM
Melhem NM see Brodsky BS
Mellman T, Lydiard RB. Posttraumatic stress disorder: characteristics and treatment. Jan e02
Melmed RD see Findling RL
Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. May 817–829
Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Yağcıoğlu AEA, Small JG. Randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. Feb 274–285
Meltzer HY, Jayathilake K. Reply to Mattes JA: High-dose olanzapine versus clozapine [letter]. Oct 1660–1661
Merchán-Naranjo J see Fraguas D
Mergl R see Hegerl U
Meyer JM. Sexual dysfunction in patients treated with atypical antipsychotics. Sept e26
Meyer RE see Gelenberg AJ; Salzman C
Meyer WJ see Sajatovic M
Meyers AL see Kornstein SG
Meyers BS see Rothschild AJ
Meyers OI, Youngstrom EA. Parent General Behavior Inventory subscale to measure sleep disturbance in pediatric bipolar disorder. May 840–843
Middleton L see Hartung DM
Miettunen J see Karlsson L
Miller BL see Rankin KP
Miller CJ, Flory JD, Miller SR, Harty SC, Newcorn JH, Halperin JM. Childhood attention-deficit/hyperactivity disorder and the emergence of personality disorders in adolescence: a prospective follow-up study. Sept 1477–1484
Miller IW, Keitner GI, Ryan CE, Uebelacker LA, Johnson SL, Solomon DA. Family treatment for bipolar disorder: family impairment by treatment interactions. May 732–740
Miller LJ, Bishop JR, Fischer JH, Geller SE, Macmillan C. Balancing risks: dosing strategies

for antidepressants near the end of pregnancy [ASCP CORNER]. Feb 323–324
Miller MD see Karp JF
Miller SR see Miller CJ
Miltenberger PD see Brandon AR
Minichiello WE see Baer L
Mintzes B see Jureidini J
Mirsky J, Kohn R, Levav I, Grinshpoon A, Ponizovsky AM. Psychological distress and common mental disorders among immigrants: results from the Israeli-based component of the World Mental Health Survey. Nov 1715–1720
Mischoulon D, Fava M. Are nutritional supplements ready for prime time? [ASCP CORNER] Sept 1497–1498
Mitchell JE see Mueller A
Mitropoulos PA see Mitsonis CI
Mitsonis CI, Mitropoulos PA, Dimopoulos NP, Kararizou EG, Psarra VV, Tsakiris FE, Katsanou M-NE. Vardenafil in the treatment of erectile dysfunction in outpatients with chronic schizophrenia: a flexible-dose, open-label study. Feb 206–212
Miyahara S see Gilmer WS; Marangell LB; McGrath PJ
Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection. June 959–965
Mojtabai R, Olfson M. National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the National Comorbidity Survey Replication. July 1064–1074
Möller H-J see Brunnauer A; Dittmann S
Money R see Aaronson CJ
Montagnani MS see Borri C
Montaresi S see Borri C
Moreno D see Fraguas D
Morgan DW see Gualtieri CT
Morio A see Ujike H
Morita Y see Ujike H
Mørland J see Bramness JG
Morrato EH, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. Feb 316–322
Morris DW see McGrath PJ
Mortensen PB see Laursen TM
Moscardino U, Scrimin S, Capello F, Altoè G, Axia G. Psychological adjustment of adolescents 18 months after the terrorist attack in Beslan, Russia: a cross-sectional study. May 854–859
Moser DJ see Beglinger LJ
Mosquera F see González-Pinto A
Moutier C see Zisook S
Mueller A, Mueller U, Silbermann A, Reinecker H, Bleich S, Mitchell JE, de Zwaan M. Randomized, controlled trial of group cognitive-behavioral therapy for compulsive buying disorder: posttreatment and 6-month follow-up results. July 1131–1138
Mueller M see Husain MM; McClintock SM
Mueller U see Mueller A
Muhonen LH, Lönnqvist J, Juva K, Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. Mar 392–399
Mulcare L see Pundiak TM
Müller-Oerlinghausen B see Berghöfer A
Mulsant BH see Rothschild AJ
Multiple Meta-Analyses of New Generation Antidepressants (MANGA) Study Group see Watanabe N
Munk-Olsen T see Laursen TM
Mur M, Portella MJ, Martínez-Arán A, Pifarré J, Vieta E. Long-term stability of cognitive impairment in bipolar disorder: a 2-year follow-up study of lithium-treated euthymic bipolar patients. May 712–719
Murphy BP. Inconclusive evidence for the efficacy of olanzapine in the treatment of negative symptoms in schizophrenia [letter with reply]. Jan 164–165
Musgnung J see Rothbaum BO
Muzina DJ see Gao K
Naber D see Fleischhacker WW
Nakagawa A see Cipriani A; Watanabe N
Nakano I see Honda T
Narrow WE see Hatzenbuehler ML
Nedjar H see Rahme E
Neimark GB. Talking about the Internet [letter with reply]. Nov 1831
Nejtek VA, Avila M, Chen L-A, Zielinski T, Djokovic M, Podawiltz A, Kaiser K, Bae S, Rush AJ. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? a randomized, double-blind trial. Aug 1257–1266
Nelligan JA, Loftis JM, Matthews AM, Zucker BL, Linke AM, Hauser P. Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: results from a retrospective chart review. May 810–816
Nelson EB see McElroy SL
Nelson JC, Thase ME, Khan A. Are antidepressants effective? what's a clinician to think? [ASCP CORNER] June 1014–1015
Nelson JC see Trivedi MH
Neubecker KE see Weiner MF
Neumeister A see Bonne O
Neutel CI see Bramness JG
Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'Italien GJ, Nys M, Carson WH, McQuade RD. Multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. July 1046–1056
Newcomer JW see Fleischhacker WW; Morrato EH
Newcorn JH see Miller CJ
Nierenberg AA. Analysis of the efficacy of treatments for bipolar depression. Suppl 5, 4–8
Nierenberg AA. Effective agents in treating bipolar depression. Oct e29
Nierenberg AA see Gilmer WS; McGrath PJ
Nillni YI see Javaras KN
Ninan PT see Gelenberg AJ
Nino J see Loebl T
Nitsche MA see Fregni F
Nizny MM. Review of Renik O: *Practical Psychoanalysis for Therapists and Patients.* Sept 1503
Noble JM see Recupero PR
Nolen WA see Kaymaz N
Nomura A see Ujike H
Nordentoft M see Laursen TM
Norman P see Ford AH
Norman-Nott A see Fazel S
Noronha MM see Bond DJ
Nowakowska C, Sachs GS, Zarate CA Jr, Marangell LB, Calabrese JR, Goldberg JF, Ketter TA. Increased rate of non–right-handedness in patients with bipolar disorder [letter]. May 866–867
Nuamah IF see Meltzer HY
Nugent AC see Bonne O
Nunes EV see Blanco C
Nutt D see Trivedi MH
Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. Suppl E1, 4–7
Nys M see Newcomer JW
O'Donnell C see Berger GE
O'Donnell M see Bryant RA
O'Donnell ML see Bryant RA
O'Donovan MC see Ravindran AV
Ogburn E see Blanco C
Okahisa Y see Ujike H
Olfson M, Marcus SC. Case-control study of antidepressants and attempted suicide during early phase treatment of major depressive episodes. Mar 425–432
Olfson M see Blanco C; Fleischhacker WW; Mojtabai R
Oliff HS see Tohen M
Omori IM see Watanabe N
Oppo A see Borri C; Mauri M
Oquendo M see Brodsky BS
Oquendo MA see Mann JJ; Perez-Rodriguez MM; Sher L
O'Reardon JP see Janicak PG
Ösby U see Fleischhacker WW
Otto MW see Simon NM
Ottoni GL see Bisol LW
Owen RR see Hudson TJ
Pachas GN see Loebl T
Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. May 759–768
Palomo T see Rubio G
Pantelis C see Karsz FR
Papakostas GI. Tolerability of modern antidepressants. Suppl E1, 8–13
Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, Fava M. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. Aug 1287–1292

Paparrigopoulos T, Karaiskos D, Liappas J. Quetiapine: another drug with potential for misuse? a case report [letter]. Jan 162–163
Parellada M see Fraguas D
Pariante CM see Su K-P
Park HJ see Chang JS
Pascual JC, Soler J, Puigdemont D, Pérez-Egea R, Tiana T, Alvarez E, Pérez V. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. Apr 603–608
Pascual-Leone A see Demirtas-Tatlidede A; Fregni F
Patel MX, de Zoysa N, Bernadt M, David AS. Cross-sectional study of patients' perspectives on adherence to antipsychotic medication: depot versus oral. Oct 1548–1556
Paulsen JS see Beglinger LJ
Paulson HL see Beglinger LJ
Paulsson B see Weisler RH
Paulzen M, Gründer G. Toxic psychosis after intake of the hallucinogen salvinorin A [letter]. Sept 1501–1502
Pavlic D see Rankin KP
Paz GEG see Bisol LW
Pearlman C see Demirtas-Tatlidede A
Pecenak J see Dossenbach M
Peciukaitiene D see Dossenbach M
Pedersen R see Rothbaum BO
Pelkonen M see Karlsson L
Peng X see Ascher-Svanum H
Perahia DGS, Quail D, Desaiah D, Corruble E, Fava M. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. Jan 95–105
Perel JM see Sit DK
Pérez V see Pascual JC
Pérez-Egea R see Pascual JC
Perez-Rodriguez MM, Baca-Garcia E, Diaz-Sastre C, Garcia-Resa E, Ceverino A, Saiz-Ruiz J, Oquendo MA, de Leon J. Low serum cholesterol may be associated with suicide attempt history. Dec 1920–1927
Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA, on behalf of the Comparison of Atypicals in First Episode Study Group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. Jan 106–113
Perlis RH. Clinical decision making in the treatment of mania. Suppl 5, 16–21
Peselow ED see Pundiak TM
Petersen TJ, Huffman JC, Weiss AP, Blais MA, Andreotti CF, Horwitz MB, Birnbaum RJ. Reach of benchmark psychiatric trial results to community-based providers: a case study of CATIE. July 1081–1086
Petrides G see Husain MM; McClintock SM
Petti TA. Review of Vitiello B, Masi G, Marazziti D (eds): *Handbook of Child and Adolescent Psychopharmacology*. May 869
Pettinati HM see Ciraulo DA
Petty CR see Biederman J
Peuskens J see van Winkel R
Pezzetta F see Mascitelli L
Pfeffer CR. Review of Luby JL (ed): *Handbook of Preschool Mental Health: Development, Disorders, and Treatment*. Apr 684–685
Pfennig A see Berghöfer A
Pian J see Chronis-Tuscano A
Pickering RP see Goldstein RB; Pulay AJ; Grant BF; Stinson FS
Pifarré J see Mur M
Pikalov A see Trivedi MH
Pike SK, Kuperman S. Review of Doyle BB: *Understanding and Treating Adults With Attention Deficit Hyperactivity Disorder*. July 1194–1195
Pinchera A see Mauri M
Pinninti NR see Mago R
Podawiltz A see Nejtek VA
Polari A see Berger GE
Polini M see Mauri M
Pollack DA see Hartung DM
Pollack MH see Simon NM
Pollock BG see Salzman C
Ponce G see Rubio G
Ponizovsky AM see Mirsky J
Pope HG Jr see Javaras KN
Portella MJ see Mur M
Posey DJ see McDougle CJ
Post JM. Review of Haltzman S and DiGeronimo TF: *Secrets of Happily Married Men: Eight Ways to Win Your Wife's Heart Forever*. Mar 504
Potter WZ see Gelenberg AJ
Poyurovsky M see Glick ID
Prakash R. Review of Jobes DA: *Managing Suicidal Risk: A Collaborative Approach*. May 869–870
Prashad SJ see Marangell LB
Prather R see Zisook S
Pratt RD see Findling RL
Preda A. Shared decision making in schizophrenia treatment [letter with reply]. Feb 326–327
PREDICT-HD Investigators of the Huntington Study Group see Beglinger LJ
Prelipceanu D see Tohen M
Preskorn SH. Reply to Hamamura T: Intrinsic activity of aripiprazole is not 30% of dopamine, but only about 6% under ideal antipsychotic therapy [letter]. May 863–865
Press DZ see Demirtas-Tatlidede A
Proffitt T-M see Berger GE
Psarra VV see Mitsonis CI
Puigdemont D see Pascual JC
Pulay AJ, Dawson DA, Hasin DS, Goldstein RB, Ruan WJ, Pickering RP, Huang B, Chou SP, Grant BF. Violent behavior and DSM-IV psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Jan 12–22
Pulay AJ see Grant BF; Stinson FS
Pundiak TM, Case BG, Peselow ED, Mulcare L. Discontinuation of maintenance selective serotonin reuptake inhibitor monotherapy after 5 years of stable response: a naturalistic study. Nov 1811–1817
Putkonen H see Joffe G
Qi Y see Trivedi MH
Qian Y see Yu H
Quail D see Perahia DGS
Queller S see Beglinger LJ
Racy JC. Review of Loewenthal K: *Religion, Culture, and Mental Health*. Dec 1986
Rado JT, Dowd S, Janicak PG. Reply to Kapoor S: Transcranial magnetic stimulation: clinical applications beyond depression [letter]. July 1191–1192
Rado JT see Janicak PG
Rahme E, Dasgupta K, Turecki G, Nedjar H, Galbaud du Fort G. Risks of suicide and poisoning among elderly patients prescribed selective serotonin reuptake inhibitors: a retrospective cohort study. Mar 349–357
Raidma M see Joffe G
Raj YP. Atomoxetine-associated hemospermia: a case report [letter]. July 1189
Rajan B see Antony JT
Rakofsky JJ, Ghaemi SN. Is aripiprazole an efficacious adjunct for unipolar depression? [letter with reply] June 1021–1022
Ramacciotti D see Borri C
Rambelli C see Borri C
Ramos FLP see Bisol LW
Rankin KP, Santos-Modesitt W, Kramer JH, Pavlic D, Beckman V, Miller BL. Spontaneous social behaviors discriminate behavioral dementias from psychiatric disorders and other dementias. Jan 60–73
Rao S see Zisook S
Rapaport MH, Hales DJ. Qualifications for recertification: an important but evolving set of standards [ASCP Corner]. Nov 1829
Räsänen P see Joffe G
Raskind M see Salzman C
Rasmussen K see Husain MM
Rauch S see Simon NM
Ravindran AV, Kennedy SH, O'Donovan MC, Fallu A, Camacho F, Binder CE. Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. Jan 87–94
Ravindran AV see Steiner M
Ray S see Aaronson CJ
Razzini C see Leo R
Recupero PR, Harms SE, Noble JM. Googling suicide: surfing for suicide information on the Internet. June 878–888
Recupero PR, Harms SE, Noble JM. Reply to Neimark GB: Talking about the Internet [letter]. Nov 1831
Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. Aug 1228–1236
Reimherr FW see Robison RJ
Reinecker H see Mueller A
Remington G see Uchida H

Renaud J see McGirr A
Reus VI. Qualifications for recertification: an important but evolving set of standards [Commentary: ASCP Corner]. Nov 1829–1830
Reynolds CF III see Karp JF
Reynolds EK see Daughters SB
Reynolds RF see Strom BL
Ricciardulli S see Borri C
Richardson J, Steiger H, Schmitz N, Joober R, Bruce KR, Israel M, Gauvin L, Anestin AS, Dandurand C, Howard H, de Guzman R. Relevance of the 5-HTTLPR polymorphism and childhood abuse to increased psychiatric comorbidity in women with bulimia-spectrum disorders. June 981–990
Richardson J see Steiger H
Riedel M see Dittmann S
Rifkin JB see Brandon AR
Rigotti NA see Culhane MA
Rihmer Z, Gonda X, Tondo L. Lithium and suicidal behavior in patients with bipolar disorder [letter]. Nov 1831–1832
Rinaldi S see Mauri M
Risby ED. Review of Riba MB, Balon R: *Competency in Combining Pharmacotherapy and Psychotherapy: Integrated and Split Treatment.* Apr 683
Roback HB see Sacks DN
Robb AS see Chronis-Tuscano A
Roberts JL see Javaras KN
Roberts MW. Review of Stubbe D: *Child and Adolescent Psychiatry: A Practical Guide.* Jan 167
Robison RJ, Reimherr FW, Marchant BK, Faraone SV, Adler LA, West SA. Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis. Feb 213–221
Rodríguez-Jiménez R see Rubio G
Rogowski R see Scharf M
Romano A see Mauri M
Romeo F see Leo R
Rooney ME see Chronis-Tuscano A
Roos RAC see van Duijn E
Rosenbaum JF see Gelenberg AJ
Rosenheck RA see Mohamed S; Satterthwaite TD
Rosenthal NR see Javaras KN
Ross-Degnan D see Law MR
Rosso G see Maina G
Roth BL. High-dose olanzapine for treatment-resistant schizophrenia [commentary]. Feb 176–177
Roth T see Scharf M
Rothbaum BO, Davidson JRT, Stein DJ, Pedersen R, Musgnung J, Tian XW, Ahmed S, Baldwin DS. Pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo. Oct 1529–1539
Rothbaum BO, Killeen TK, Davidson JRT, Brady KT, Connor KM, Heekin MH. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor–resistant civilian posttraumatic stress disorder. Apr 520–525
Rothschild AJ, Winer J, Flint AJ, Mulsant BH, Whyte EM, Heo M, Fratoni S, Gabriele M, Kasapinovic S, Meyers BS, for the Study of Pharmacotherapy of Psychotic Depression (STOP-PD) Collaborative Study Group. Missed diagnosis of psychotic depression at 4 academic medical centers. Aug 1293–1296
Roy A see Meltzer HY
Ruan WJ see Goldstein RB; Grant BF; Pulay AJ; Stinson FS
Rubinow DR see Schmidt PJ; Steinberg EM
Rubio G, Manzanares J, Jiménez M, Rodríguez-Jiménez R, Martínez I, Iribarren MM, Jiménez-Arriero MA, Ponce G, Palomo T. Use of cocaine by heavy drinkers increases vulnerability to developing alcohol dependence: a 4-year follow-up study. Apr 563–570
Rucci P see Borri C; Mauri M
Ruggero CJ see Zimmerman M
Ruiz I see González-Pinto A
Ruiz de Azúa S see González-Pinto A
Ruiz-Sancho A see Fraguas D
Rummans TA see Husain MM; McClintock SM
Rupprecht R see Baghai TC
Rush AJ see Gilmer WS; Husain MM; McClintock SM; McGrath PJ; Nejtek VA
Ruskin JN see Strom BL
Ruuttu T see Karlsson L
Ryan CE see Miller IW
Ryan ND see Goldstein BI
Rybakowski J see Berghöfer A
Rybakowski JK. Aripiprazole joins the family of second-generation mood stabilizers [letter]. May 862–863
Rytsälä HJ see Holma KM
Sachs GS see Nowakowska C
Sacks DN, Roback HB. Review of Zayfert C, Becker CB: *Cognitive-Behavioral Therapy for PTSD: A Case Formulation Approach.* Aug 1342
Saha TD see Goldstein RB; Grant BF; Stinson FS
Sahota PKC, Knowler WC, Looker HC. Depression, diabetes, and glycemic control in an American Indian community. May 800–809
Saiz-Ruiz see Perez-Rodriguez MM
Sajatovic M, Coconcea N, Ignacio RV, Blow FC, Hays RW, Cassidy KA, Meyer WJ. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. Jan 41–46
Saksa JR see Aaronson CJ; Woods SW
Salamero M see Martinez-Aran A
Sallee FR see Findling RL
Salomon RM. Review of Blumenfield M, Strain JJ (eds): *Psychosomatic Medicine.* Apr 684
Salomon RM. Review of Leigh H, Streltzer J (eds): *Handbook of Consultation-Liaison Psychiatry.* Apr 684
Salomon RM. Review of Stern TA, Rosenbaum JF, Fava M, Biederman J, Rauch SL (eds): *Massachusetts General Hospital Comprehensive Clinical Psychiatry.* Dec 1988
Salvadore G see Machado-Vieira R
Salvi V, Fagiolini A, Swartz HA, Maina G, Frank E. Use of antidepressants in bipolar disorder. Aug 1307–1318
Salvi V see Weinmann S
Salzman C, Jeste DV, Meyer RE, Cohen-Mansfield J, Cummings J, Grossberg GT, Jarvik L, Kraemer HC, Lebowitz BD, Maslow K, Pollock BG, Raskind M, Schultz SK, Wang P, Zito JM, Zubenko GS. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. June 889–898
Sampson S see Husain MM; McClintock SM
Sampson SM see Avery DH; Janicak PG
Sanacora G. New understanding of mechanisms of action of bipolar medications. Suppl 5, 22–27
Sanchez-Moreno J see Martinez-Aran A
Santini F see Mauri M
Santos-Modesitt W see Rankin KP
Sareen J see Bolton JM
Sargeant MN see Daughters SB
Sartorius N see Fleischhacker WW
Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. Meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. Dec 1869–1879
Saul MI see Coley KC
Sayrs JHR see Linehan MM
Scharf M, Rogowski R, Hull S, Cohn M, Mayleben D, Feldman N, Ereshefsky L, Lankford A, Roth T. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study. Oct 1557–1564
Scheen A see van Winkel R
Scheiber SC. Review of Spitzer RL, First MB, Williams JBW, Gibbon M (eds): *DSM-IV-TR Case Book, vol. 2: Experts Tell How They Treated Their Own Patients.* Feb 330–331
Schenck CH see Khawaja IS
Scheunemann W see Hegerl U
Schmidt PJ, Steinberg EM, Rubinow DR. Why study reproductive neuroscience? a clinical perspective [In the Author's Own Words]. June 972
Schmidt PJ see Steinberg EM
Schmitz N see Richardson J
Schneier FR see Vesga-López O
Schoenfeld DA see Culhane MA
Schoenfeld S see Biederman J
Scholle SH see Wisner KL
Schule C see Baghai TC
Schultz JF see Stensland MD
Schultz SK see Salzman C
Schütze M see Hegerl U
Schuyten G see Colins O
Schwarz MJ see Dittmann S
Schwenk TL, Gorenflo DW, Leja LM. Survey on the impact of being depressed on the professional status and mental health care of physicians. Apr 617–620

Schwenk TL, Leja LM. Reply to Youssef NA: Depression in physicians: hyperfunctioning depression or professional depression? [letter] Oct 1661–1662
Scipio TM see Coley KC
Scrimin S see Moscardino U
Seemüller F see Dittmann S; Hegerl U
Séguin M see McGirr A
Seidman LJ see Biederman J
Seifert CA see Papakostas GI
Seliverstov MI see Shiovitz TM
Severn DG see Griffith JM
Severus WE see Dittmann S
Seymour KE see Chronis-Tuscano A
Shajahan P see Taylor M
Shammi C see Uchida H
Sharif Z. Side effects as influencers of treatment outcome. Suppl 3, 38–43
Sharif ZA see Kane JM
Sharma S see Shiovitz TM
Shear MK see Aaronson CJ
Shekhar A see Tohen M
Shelton RC see Gelenberg AJ
Sher L, Stanley BH, Harkavy-Friedman JM, Carballo JJ, Arendt M, Brent DA, Sperling D, Lizardi D, Mann JJ, Oquendo MA. Depressed patients with co-occurring alcohol use disorders: a unique patient population. June 907–915
Shi Y see Yu H
Shimada N see Kishimoto T
Shiovitz TM, Song JL, Manlosa NB, Seliverstov MI, Sharma S. Extreme creatine phosphokinase elevation in a 20-year-old man participating in a clinical trial of major depressive disorder [letter]. Nov 1832–1834
Signoretti A see Cipriani A
Sikes CR see Friedman MJ
Sikich L. Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders. Suppl 4, 21–25
Silbermann A see Mueller A
Silove D see Bryant RA
Silver H. Selective serotonin reuptake inhibitor add-on therapy for the negative symptoms of schizophrenia [letter]. Jan 163–164
Silverman BL see Ciraulo DA
Simon NM, Connor KM, Lang AJ, Rauch S, Krulewicz S, LeBeau RT, Davidson JRT, Stein MB, Otto MW, Foa EB, Pollack MH. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. Mar 400–405
Simpson SD see Steiner M
Siracusano A see Leo R
Siris SG see Glick ID
Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. Apr 652–658
Skurtveit S see Bramness JG
Small JG see Meltzer HY
Smith RP, Larkin GL, Southwick SM. Trends in U.S. emergency department visits for anxiety-related mental health conditions, 1992–2001. Feb 286–294
Smith SM see Grant BF; Stinson FS
Smith WT see Bielski RJ
Smits JAJ see Hofmann SG
Smulevich AB see Dossenbach M
Snow D see Marangell LB
Snow J see Bonne O
Soares CN. Practical strategies for diagnosing and treating depression in women: menopausal transition. Oct e30
Soares JC see Machado-Vieira R
Soeteman DI, Hakkaart-van Roijen L, Verheul R, Busschbach JJV. Economic burden of personality disorders in mental health care. Feb 259–265
Soler J see Pascual JC
Solomon DA see Miller IW
Song JL see Shiovitz TM
Soreca I see Fagiolini A; Fleet-Michaliszyn SB
Soumerai SB see Law MR
Southwick SM see Smith RP
Souza DO see Machado-Vieira R
Soyez V see Colins O
Spencer TJ, Adler LA, Weisler RH, Youcha SH. Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study. Sept 1437–1448
Spencer TJ, Landgraf JM, Adler LA, Weisler RH, Anderson CS, Youcha SH. Attention-deficit/hyperactivity disorder–specific quality of life with triple-bead mixed amphetamine salts (SPD465) in adults: results of a randomized, double-blind, placebo-controlled study. Nov 1766–1775
Sperling D see Sher L
Spirling LI, Stapleton JA, Sutherland G. Suicidal ideation and varenicline: a possible case of mistaken adverse drug reaction? [letter] Nov 1834–1835
Spitzer C, Barnow S, Völzke H, John U, Freyberger HJ, Grabe HJ. Trauma and posttraumatic stress disorder in the elderly: findings from a German community study. May 693–700
Stahl SM. L-Methylfolate: a vitamin for your monoamines [Brainstorms]. Sept 1352–1353
Stahl SM. Sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? [Brainstorms] Nov 1673–1674
Stahl SM see Papakostas GI
Stanley B see Brodsky BS
Stanley BH see Sher L
Staples JL see Gordon JS
Stapleton JA see Spirling LI
Steiger H, Joober R, Gauvin L, Bruce KR, Richardson J, Israel M, Anestin AS, Groleau P. Serotonin-system polymorphisms (5-HTTLPR and –1438G/A) and responses of patients with bulimic syndromes to multimodal treatments. Oct 1565–1571
Steiger H see Richardson J
Stein B see Wisner KL
Stein DJ see Rothbaum BO
Stein MA see Chronis-Tuscano A
Stein MB see Simon NM
Steinberg EM, Rubinow DR, Bartko JJ, Fortinsky PM, Haq N, Thompson K, Schmidt PJ. Cross-sectional evaluation of perimenopausal depression. June 973–980
Steinberg EM see Schmidt PJ
Steiner M, Ravindran AV, LeMelledo J-M, Carter D, Huang JO, Anonychuk AM, Simpson SD. Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. June 991–998
Stening G see Weisler RH
Stensland MD, Schultz JF, Frytak JR. Diagnosis of unipolar depression following initial identification of bipolar disorder: a common and costly misdiagnosis. May 749–758
Stern WM see Demirtas-Tatlidede A
Stewart JW see McGrath PJ
Stigler KA see McDougle CJ
Stinson FS, Dawson DA, Goldstein RB, Chou SP, Huang B, Smith SM, Ruan WJ, Pulay AJ, Saha TD, Pickering RP, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV narcissistic personality disorder: results from the Wave 2 National Epidemiologic Survey on Alcohol and Related Conditions. July 1033–1045
Stinson FS see Goldstein RB; Grant BF
Stout JC see Beglinger LJ
Straits-Tröster K see Calhoun PS
Stringer CA see Brandon AR
Strober MA see Goldstein BI
Strom BL, Faich GA, Reynolds RF, Eng SM, D'Agostino RB, Ruskin JN, Kane JM. Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics. Jan 114–121
Stubbe DE. Review of Garralda ME, Flament M (eds): *Working With Children and Adolescents: An Evidence-Based Approach to Risk and Resilience*. Feb 330
Study of Pharmacotherapy of Psychotic Depression (STOP-PD) Collaborative Study Group see Rothschild AJ
Su K-P, Huang S-Y, Chiu T-H, Huang K-C, Huang C-L, Chang H-C, Pariante CM. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. Apr 644–651
Sudak HS. Review of Clarkin JF, Yeomans FE: *Psychotherapy for Borderline Personality: Focusing on Object Relations*. June 1023–1024
Sun B see Tohen M
Suppes T see Gonzalez R; Marangell LB; Weisler RH
Sureddi S see Marangell LB
Sutherland G see Spirling LI
Suwalska A see Berghöfer A
Swartz CM. ECT not proven for atypical depression [letter with reply]. 1662–1663
Swartz HA. Role of psychosocial interventions in bipolar II disorder: what do we know? May e15

Swartz HA see Salvi V
Sysko R, Walsh BT. Reply to Vieta E: Increasing rates of placebo response over time in mania studies [letter]. Apr 681–682
Szulc A see Dossenbach M
Tabares-Seisdedos R see Martinez-Aran A
Takala P see Joffe G
Takamatsu J see Honda T
Tang C-S see Gau SS-F
Tanguay PE. Review of Schreibman L: *Science and Fiction of Autism.* Sept 1503–1504
Tanguay PE. Review of Thompson T: *Making Sense of Autism.* Nov 1836–1837
Tariot PN. Psychosis and agitation in dementia: should general psychiatrists care? [commentary] Mar 339–340
Taylor CC see Lauriello J
Taylor M, Shajahan P, Lawrie SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. Feb 240–245
Tchoukhine E see Joffe G
Tek C see Woods SW
Tesauro M see Leo R
Thall M see Demirtas-Tatlidede A
Thapa P see Hudson TJ
Thase ME. Maintenance therapy for bipolar disorder. Nov e32
Thase ME. Management of patients with treatment-resistant depression. Mar e08
Thase ME. Selecting appropriate treatments for maintenance therapy for bipolar disorder. Suppl 5, 28–35
Thase ME see Avery DH; Dunner DL; Gelenberg AJ; Gilmer WS; Marangell LB; Nelson JC; Trivedi MH; Weisler RH
Thienhaus OJ. Review of Fulford KWMB, Thornton T, Graham G (eds): *Oxford Textbook of Philosophy and Psychiatry.* May 868
Thomas J see Ford AH
Thompson J. State of the Society [ASCP Corner]. Jan 160–161
Thompson K see Steinberg EM
303 Study Group see Adler LA
Thrush CR see Hudson TJ
Tian XW see Rothbaum BO
Tiana T see Pascual JC
Tibben A see van Duijn E
Tierney MC see Huey ED
Timman R see van Duijn E
Tin A see Brodsky BS
Tochilov V see Tohen M
Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD, Banov M, Shekhar A, Aaronson ST, Bardenstein L, Grecu-Gabos I, Tochilov V, Prelipceanu D, Oliff HS, Kryzhanovskaya L, Bowden C. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. Nov 1776–1789
Tohen M see Ascher-Svanum H
Tolliver BK see Gao K
Tondo L see Rihmer Z
Torrent C see Martinez-Aran A
Tortolani C see Zimmerman M
Toyoda H see Honda T
Tran Q-V see Trivedi MH
Treuer T see Dossenbach M
Trivedi MH, Hollander E, Nutt D, Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. Feb 246–258
Trivedi MH, Thase ME, Fava M, Nelson JC, Yang H, Qi Y, Tran Q-V, Pikalov A, Carlson BX, Marcus RN, Berman RM. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. Dec 1928–1936
Trivedi MH see Brandon AR; Gelenberg AJ; Gilmer WS; McGrath PJ
Tsakiris FE see Mitsonis CI
Tsuang JW see Hernandez V
Tsuang MT see Javaras KN
Tucker VL see Papakostas GI
Tuisku V see Karlsson L
Turecki G see McGirr A; Rahme E
Turkin S see Fagiolini A
Tzang R-F see Gau SS-F
Uchida H, Mamo DC, Kapur S, Labelle A, Shammi C, Mannaert EJL, Mann SW, Remington G. Monthly administration of long-acting injectable risperidone and striatal dopamine D_2 receptor occupancy for the management of schizophrenia. Aug 1281–1286
Uchida H see Mamo DC
Uebelacker LA see Miller IW
Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, Kodama M, Ishihara T, Kuroda S. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. Sept 1416–1422
Valuck RJ see Morrato EH
Vance A see Karsz FR
van den Broek WW see Heijnen WTC
van der Mast RC see van Duijn E
van der Schoot TAW see Alisic E
van Duijn E, Kingma EM, Timman R, Zitman FG, Tibben A, Roos RAC, van der Mast RC. Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first-degree relatives. 1804–1810
Van Eyck D see van Winkel R
van Ginkel JR see Alisic E
Vanhala M see Koponen H
van Oppen P see Cuijpers P
van Os J see Kaymaz N; van Winkel R
van Straten A see Cuijpers P
van Winkel R, De Hert M, Wampers M, Van Eyck D, Hanssens L, Scheen A, Peuskens J. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. Mar 472–479
van Winkel R, van Os J, Celic I, Van Eyck D, Wampers M, Scheen A, Peuskens J, De Hert M. Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. Aug 1319–1327
van Winkel R see Weinmann S
Varallo-Bedarida G see Baghai TC
Vega P see González-Pinto A
Verduin ML see Gao K
Verheul R see Soeteman DI
Vermeiren R see Colins O
Vesga-López O, Schneier FR, Wang S, Heimberg RG, Liu S-M, Hasin DS, Blanco C. Gender differences in generalized anxiety disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Oct 1606–1616
Vieta E. Defining the bipolar spectrum and treating bipolar II disorder. Apr e12
Vieta E. Observational, pragmatic, and clinical trials in bipolar disorder. Sept e27
Vieta E, Cruz N. Increasing rates of placebo response over time in mania studies [letter with reply]. Apr 681–682
Vieta E see González-Pinto A; Martinez-Aran A; Mur M; Tohen M
Villero S, Fraguas D. Gender imbalance in clinical trials in schizophrenia [letter]. Mar 498–499
Vitcu I see Mamo DC
Volpe FM. 8-week, open-label trial of duloxetine for comorbid major depressive disorder and chronic headache. Sept 1449–1454
Völzke H see Spitzer C
von Schacky C see Baghai TC
Vythilingam M see Bonne O
Wadekar M see Bystritsky A
Wagner KD. Recognizing parents' symptoms, obesity, and bipolar depression. Dec 1937
Wagner SA see Chronis-Tuscano A
Waheed W. Review of Dulcan MK (ed): *Helping Parents, Youth, and Teachers Understand Medications for Behavioral and Emotional Problems: A Resource Book of Medication Information Handouts, 3rd ed.* June 1025
Walsh BT see Javaras KN; Sysko R
Wampers M see van Winkel R
Wang C see Beglinger LJ
Wang P see Salzman C
Wang S see Hasin DS; Vesga-López O
Wang T-Y see Yeh Y-W
Warden D see Gilmer WS
Wassermann EM see Huey ED
Watanabe K see Kishimoto T
Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA, on behalf of the Multiple Meta-Analyses of New Generation Antidepressants (MANGA) Study Group. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis. Sept 1404–1415
Waternaux CM see Mann JJ
Watson DB see Beglinger LJ
Webb RT see Abel KM

Weiden PJ. Reply to Carlat D: Apparent commercial bias in supplement [reply]. June 1020–1021
Weiden PJ see Perkins DO
Weiner MF, Neubecker KE, Bret ME, Hynan LS. Language in Alzheimer's disease. Aug 1223–1227
Weinmann S, Hoerger S, Erath M, Kilian R, Gaebel W, Becker T. Implementation of a schizophrenia practice guideline: clinical results. Aug 1299–1306
Weinmann S, Salvi V, van Winkel R. Impact of mentorship. Aug 1298
Weisler RH, Calabrese JR, Thase ME, Arvekvist R, Stening G, Paulsson B, Suppes T. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. May 769–782
Weisler RH see Adler LA; Spencer TJ
Weiss AP see Petersen TJ
Weiss K see Bielski RJ
Welge JA see McElroy SL
West SA see Robison RJ
West TM see Dossenbach M
Westermeyer J. Review of Coffey CE, McAllister TW, Silver JM, the Fellows of the American Neuropsychiatric Association: *Guide to Neuropsychiatric Therapeutics*. Sept 1504–1505
White KS see Aaronson CJ
Whitehead R see Coley KC
Whitmyer VG see Kornstein SG
Whyte EM see Karp JF; Rothschild AJ
Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Mar 341–348
Wilson AT see Gordon JS
Winer J see Rothschild AJ
Wing YK see Lam SP
Wisdom JP see Hartung DM
Wisner KL, Scholle SH, Stein B. Perinatal disorders: advancing public health opportunities. Oct 1602–1605
Wisner KL see Sit DK
Wisniewski SR see Gilmer WS; Marangell LB; McGrath PJ
Wohlreich MM see Kornstein SG
Wolf DH see Satterthwaite TD
Wood S see Berger GE; Bonne O
Wood SJ see Karsz FR
Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Apr 546–554
Woods SW see Aaronson CJ
Wu AD see Bystritsky A
Wu Y-Y see Gau SS-F
Xie C see Yu H
Yağcıoğlu AEA see Meltzer HY
Yagi G see Kishimoto T
Yamamoto K see Honda T
Yang H see Trivedi MH
Yang M see Goldstein BI
Yatham LN see Bond DJ
Yeh Y-W, Wang T-Y, Huang C-C, Chen Y-C. Late-onset hypersensitivity reaction with leukopenia and thrombocytopenia induced by oxcarbazepine treatment in a patient with schizoaffective disorder [letter]. Apr 676–678
Yonkers KA, Lin H, Howell HB, Heath AC, Cohen LS. Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. Apr 659–665
Youcha SH see Spencer TJ
Young D see Zimmerman M
Youngstrom EA, Frazier TW, Demeter C, Calabrese JR, Findling RL. Developing a 10-item mania scale from the Parent General Behavior Inventory for Children and Adolescents. May 831–839
Youngstrom EA see Meyers OI
Youssef NA. Depression in physicians: hyperfunctioning depression or professional depression? [letter with reply] Oct 1661–1662
Yu H, Zhang Z, Shi Y, Bai F, Xie C, Qian Y, Yuan Y, Deng L. Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. July 1104–1111
Yu MWM see Lam SP
Yuan Y see Yu H
Yuen HP see Berger GE
Zach J see Dittmann S
Zajecka JM, Gutierrez SN. Oral divalproex sodium loading for adolescent outpatients with acute mania/hypomania: a report of 2 cases [letter]. June 1016–1018
Zanasi M see Leo R
Zarate CA Jr see Machado-Vieira R; Nowakowska C
Zboyan HA see Marangell LB
Zelazny J see Brodsky BS
Zhang R see Reeves H
Zhang Y see Adler LA
Zhang Z see Yu H
Zhu B see Ascher-Svanum H
Zielinski T see Nejtek VA
Zimmerman M, Francione-Witt C, Chelminski I, Young D, Tortolani C. Problems applying the DSM-IV eating disorders diagnostic criteria in a general psychiatric outpatient practice. Mar 381–384
Zimmerman M, McGlinchey JB. Why don't psychiatrists use scales to measure outcome when treating depressed patients? Dec 1916–1919
Zimmerman M, Ruggero CJ, Chelminski I, Young D. Is bipolar disorder overdiagnosed? June 935–940
Zisook S, Ganadjian K, Moutier C, Prather R, Rao S. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): lessons learned [ASCP Corner]. July 1184–1185
Zitman FG see van Duijn E
Zito JM see Salzman C
Zubenko GS see Salzman C
Zucker BL see Nelligan JA